Gapping down
In reaction to disappointing earnings/guidance:
- RPM -8.1%, LNDC -7.1%, FLXN -5.3%
Other news:
- KALV -8.4% (provided a development update on its oral plasma kallikrein inhibitor portfolio)
Analyst comments:
- FLXN -5.3% (downgraded to Hold from Buy at The Benchmark Company)
- FTNT -3.8% (downgraded to Sell from Buy at Goldman)
- COO -1% (downgraded to Sell from Neutral at Goldman)
- EXC -0.8% (downgraded to Sell from Neutral at Goldman)
- EMR -0.7% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)
